Healthineers has diligently invested its boom-generated money in the future growth of its Diagnostics business. This has come at a price of the division’s lower organic growth and margin expectations during the ‘restructuring period’ through to 2025.
The good news is that the group’s targets until 2025 remain in place as the other divisions could compensate for Diagnostics’ weaker contribution.
Healthineers reported a strong Q4 with consensus-beating figures (revenues: +3.1%; adjusted EBIT: ....
